1. Home
  2. Medical News
  3. GOLD Conference News
advertisement

Serum Hepcidin Declines After Antifibrotic Initiation in IPF

Simplified lung illustration showing subtle interstitial scarring associated with idiopathic pulmonary fibrosis
10/30/2026

Key Takeaways

  • Among clinically stable patients with IPF starting antifibrotics at a Turkish center, serum hepcidin declined significantly overall and in most individuals.
  • Greater hepcidin reductions accompanied more favorable FVC and DLCO changes, but only FVC remained independently associated after simultaneous adjustment.
  • Paired FVC and DLCO increases were significant; changes in six-minute walk distance, hemoglobin, C-reactive protein, and erythrocyte sedimentation rate were not.
  • Hepcidin change did not differ significantly between the physician-selected pirfenidone and nintedanib groups.
Idiopathic pulmonary fibrosis (IPF) can progress despite antifibrotic treatment, leaving early biological changes difficult to characterize. Serum hepcidin is a candidate measure, but its relationship to changes in lung function and later clinical outcomes remains uncertain. That uncertainty raises the question of what hepcidin measurements around treatment initiation might reveal.

Investigators in the hepcidin study in idiopathic pulmonary fibrosis enrolled 38 clinically stable adults diagnosed by the 2022 American Thoracic Society/European Respiratory Society criteria at Balıkesir University Health Practice and Research Hospital in Turkey between January and July 2025. This single-center, prospective observational cohort was assessed at treatment initiation and three months later. Treating physicians selected pirfenidone for 13 participants and nintedanib for 25 in routine care; investigators assigned neither drug, and there was no untreated control. Fasting serum hepcidin was measured by enzyme-linked immunosorbent assay (ELISA) at both visits. Within-person hepcidin change was the primary endpoint; forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), six-minute walk distance, and laboratory indicators were also assessed. Correlations and multivariable change-score analyses assessed individual-level associations separately from overall change.

Mean serum hepcidin fell from 33.00 ± 16.74 to 24.41 ± 12.42 ng/mL by month three (p < 0.001); levels declined in 30 of 38 participants (78.9%). Paired FVC and DLCO measurements also increased significantly. Six-minute walk distance and hemoglobin, C-reactive protein, and erythrocyte sedimentation rate did not change significantly.

FVC increased by 3.90 percentage points (95% CI 2.03–5.77). At the individual level, hepcidin change was associated with FVC and DLCO changes before simultaneous adjustment. In the adjusted model, only FVC change remained independently associated with hepcidin change: B = −0.848 ng/mL per percentage-point FVC increase (95% CI −1.244 to −0.452; p < 0.001). DLCO and walking-distance changes were not independently associated. The inverse FVC association persisted after further baseline-FVC adjustment and exclusion of potential outliers. Hepcidin change did not differ significantly between the physician-selected drug groups.

Three months of follow-up in a small, single-center cohort without an untreated comparator cannot establish that the drugs caused the hepcidin decline or that hepcidin predicts later benefit. Without repeated pretreatment pulmonary testing, test familiarization, measurement variation, and regression to the mean remain possible contributors to short-term functional increases; those increases do not demonstrate fibrosis reversal. Physician-selected therapy and the smaller pirfenidone subgroup constrain drug comparisons: a nonsignificant between-group difference does not establish equivalence. Dietary iron was not quantified despite monitoring of nutrition and gastrointestinal effects. Interleukin-6 and lung-tissue hepcidin/ferroportin signaling were not assessed directly, leaving a biological mechanism unconfirmed.

According to the authors, the early hepcidin change and its individual-level FVC association warrant longer follow-up and evaluation in broader cohorts. Serum hepcidin remains a candidate response measure, not an established predictor of later clinical outcomes in IPF.

Clinician Questions

Which patients with idiopathic pulmonary fibrosis were excluded from the hepcidin antifibrotic cohort?

In the Turkish cohort of clinically stable patients with IPF beginning pirfenidone or nintedanib, exclusions included an IPF exacerbation in the preceding three months, infectious or rheumatological disease, hepatic or renal failure, and known pathologically confirmed malignancy. The final analysis also excluded patients who developed major gastrointestinal adverse effects requiring a change in antifibrotic therapy; the study does not report how many, if any, met this criterion. The observed hepcidin pattern cannot simply be extended to patients with those conditions.

Did baseline anemia account for the hepcidin decline after antifibrotic treatment for idiopathic pulmonary fibrosis?

In an exploratory check among patients with IPF receiving antifibrotics, serum hepcidin still fell after investigators excluded participants with anemia at treatment initiation; baseline hepcidin did not differ significantly by anemia status. This check does not establish treatment causality or eliminate other explanations.

How were above-range serum hepcidin results handled in patients with idiopathic pulmonary fibrosis receiving antifibrotics?

For fasting serum hepcidin measurements in patients with IPF starting pirfenidone or nintedanib, specimens above the ELISA measurement range were diluted and reassayed. Investigators corrected the final concentration for the dilution factor.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free